These results indicate that tumor-specific CD8+ T cells and NK cells play a crucial role in the observed therapeutic immunity induced by DC vaccines pulsed with CMQ-treated TCLs against B16 melanoma, whereas CD4+ T cells are only partially involved in the antitumor activity. The gene discussed is CD4; the disease is neoplasm.